170 Harbor Way
Suite 300
South San Francisco, CA 94080
United States
650 550 3500
https://vaxart.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 109
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Sean N. Tucker Ph.D. | Senior VP & Chief Scientific Officer | 561.1k | N/D | 1968 |
Dr. James F. Cummings M.D. | Chief Medical Officer | 594.5k | N/D | 1966 |
Mr. Steven Lo | President, CEO & Director | N/D | N/D | 1967 |
Mr. Phillip Eric Lee | CFO, Principal Financial Officer & Principal Accounting Officer | N/D | N/D | 1988 |
Dr. Raymond D. Stapleton Jr., Ph.D. | Chief Technology Officer | N/D | N/D | 1971 |
Mr. Edward B. Berg | Senior VP & General Counsel | N/D | N/D | 1964 |
Ms. Shaily Jaini Garg | Senior Vice President of Clinical Development & Project Management | N/D | N/D | N/D |
Dr. Rajesh Kapoor Ph.D. | Senior Vice President of Quality | N/D | N/D | N/D |
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
La calificación ISS Governance QuickScore de Vaxart, Inc. a partir del 1 de mayo de 2024 es 8. Las puntuaciones principales son Auditoría: 8; Junta: 8; Derechos del accionista: 6; Compensación: 8.